Which drugs and substances act as histamine releasers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Histamine Releasers: Drugs and Substances

Several classes of drugs cause mast cell degranulation with histamine release, most notably certain muscle relaxants, opioids, NSAIDs, and volatile anesthetics, though the clinical significance varies widely between agents and patients.

Perioperative Anesthetic Agents

Muscle Relaxants (Highest Risk)

The benzylisoquinolinium compounds are the most potent histamine releasers 1:

  • D-tubocurarine, tubocurarine, pancuronium, and gallamine triethiodide - documented histamine release in human studies, though rarely used in current practice 1
  • Atracurium - causes histamine release, particularly at higher doses; can be attenuated by slow injection over 1-3 minutes 2, 3
  • Mivacurium and atracurium - should be avoided in high-risk patients 4
  • Succinylcholine - causes nonimmunologic histamine release 5

Safer alternatives: Rocuronium and vecuronium cause minimal to no histamine release and are preferred 4, 3.

Opioid Analgesics

Meperidine and morphine induce histamine increases in humans more frequently than fentanyl and sufentanil 1. In a double-blind study, 31% of patients receiving meperidine (mean 4.3 mg/kg) developed clinical signs of histamine release with plasma levels up to 49.7 ng/ml, compared to only 10% with morphine 6. Codeine has also caused cutaneous eruptions 1.

The histamine-releasing effect is due to direct mast cell activation rather than IgE-mediated mechanisms 5, 7. Reactions are dose-dependent and can be reduced by slower administration 7.

Preferred opioids: Fentanyl and remifentanil do not cause direct histamine release and are safer choices 4, 7, 6.

NSAIDs

Ketorolac deserves special mention - there is a documented lethal idiosyncratic reaction in an adult with mastocytosis, and avoidance of ketorolac is specifically recommended in adults and children with mastocytosis 1.

NSAIDs generally cause mast cell degranulation through COX-1 inhibition rather than direct histamine release 1, 8.

Other Perioperative Agents

  • Volatile anesthetics - reported to cause mast cell degranulation 1
  • Sedative hypnotics - can trigger histamine release 1
  • Protamine - causes severe systemic reactions through both IgE-mediated and nonimmunologic mechanisms 5
  • Vancomycin - rapid administration causes direct histamine release and myocardial depression; can be reduced by slow infusion of dilute solution 5

Colloids and Blood Products

  • Dextran, mannitol, and hydroxyethyl starch - listed as histamine releasers in anesthesia 5
  • Blood transfusions - can elicit systemic reactions, some IgE-mediated 5

Clinical Context and Caveats

Critical distinction: Most drug-induced histamine release represents anaphylactoid (non-IgE) reactions rather than true anaphylaxis 5, 9. The clinical presentations may be indistinguishable, but mechanistically they differ - anaphylactoid reactions release only preformed mediators (primarily histamine), while true anaphylactic reactions involve mast cell degranulation with multiple vasoactive substances 9.

Important limitation: Studies documenting drug-induced histamine release have largely been conducted in vitro or in animals and may not reflect the human response 1. Even in humans, there is no direct and invariable relationship between plasma histamine concentration and clinical effects 7.

High-risk populations: Patients with mastocytosis are at increased risk for severe reactions, though comprehensive anesthetic planning with appropriate agent selection has resulted in uncomplicated procedures in pediatric series 1.

Mitigation strategies:

  • Slow injection over 1-3 minutes reduces histamine release 2, 3
  • Pretreatment with H1 and H2 antihistamines may attenuate reactions 2, 3
  • Temperature extremes and mechanical trauma should be avoided 1, 4

Do not withhold necessary analgesics - pain itself can trigger mast cell activation, and the risk-benefit calculation favors appropriate pain control even with histamine-releasing opioids in most clinical scenarios 4.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.